KalVista Q2 2022 Earnings Report

KalVista reported results for the second fiscal quarter ended October 31, 2021, and prepared for the initiation of the KVD900 Phase 3 clinical trial and the KVD824 Phase 2 KOMPLETE clinical trial.

Key Takeaways

KalVista Pharmaceuticals reported no revenue for the second fiscal quarter ended October 31, 2021. Research and development expenses were $17.5 million, and general and administrative expenses were $6.1 million. The net loss was $19.7 million, or $(0.80) per share. Cash, cash equivalents, and marketable securities totaled $209.8 million as of October 31, 2021.

Advanced two distinct compounds in oral hereditary angioedema franchise into later stage trials.

Initiated KOMPLETE, the Phase 2 clinical trial of KVD824, currently enrolling patients.

Presented Phase 2 data for KVD900 at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting, showing rapid absorption and clinically meaningful symptom relief.

Completed an End-of-Phase 2 meeting with the FDA, confirming the Phase 3 trial design for KVD900 is expected to be appropriate to support an NDA submission.

EPS

-$0.8

Previous year: -$0.58

+37.9%

Cash and Equivalents

$46.5M

Previous year: $16.2M